Ascentage Pharma Group International
Ascentage Pharma Group International (ASPHF) Revenue
Annual & quarterly revenue history · segment & region breakdown
ASPHF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAscentage Pharma Group International trailing twelve-month (TTM) revenue is $1.35B, a decrease of 42.97% year-over-year from $0.56B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.56B | -$0.42B | -42.97% |
| 2024-12-31 | $0.98B | +$0.76B | +341.77% |
| 2023-12-31 | $0.22B | +$0.01B | +5.85% |
| 2022-12-31 | $0.21B | +$0.18B | +651.38% |
| 2021-12-31 | $0.03B | +$0.02B | +124.18% |
| 2020-12-31 | $0.01B | -$0.00B | -14.21% |
| 2019-12-31 | $0.01B | +$0.01B | +113.21% |
| 2018-12-31 | $0.01B | +$0.00B | +7.57% |
| 2017-12-31 | $0.01B | -$0.00B | -17.46% |
| 2016-12-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare ASPHF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ascentage Pharma Group International receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ascentage Pharma Group International reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from Ascentage Pharma Group International's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ASPHF revenue · 4 questionsASPHF's trailing twelve-month (TTM) revenue is $1.35B. That is a decrease of 42.97% year-over-year from $0.56B in FY2025.
▸ Source: FMP · Ascentage Pharma Group International SEC filings · GAAP · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026